Literature DB >> 20697344

Functional importance of RASSF1A microtubule localization and polymorphisms.

M El-Kalla1, C Onyskiw, S Baksh.   

Abstract

Ras association domain family protein 1A (RASSF1A) is one of the more heavily methylated genes in human cancers. In addition to promoter-specific methylation, RASSF1A polymorphisms have been identified in cancer patients. RASSF1A is a tumor suppressor protein involved in death receptor-dependent apoptosis and it is localized to microtubules. Currently, the biological importance of RASSF1A microtubule localization and the functional consequences of RASSF1A polymorphisms is not understood. In this study, we have investigated both RASSF1A microtubule association and polymorphisms. Loss of RASSF1A microtubule association resulted in the nuclear appearance of RASSF1A and the loss of association with α-, γ- and β-tubulin. Moreover, the loss of microtubule localization of RASSF1A resulted in enhanced tumor-promoting potential, as determined by a xenograft transplantation model in nude mice. It is surprising that, several RASSF1A polymorphisms also lost the ability to associate with α-, γ- and β-tubulin and lost the ability to prevent tumor formation in a xenograft nude mouse model when compared with wild-type RASSF1A. Our results demonstrate a role for RASSF1A microtubule localization in eliciting its tumor suppressor function. In addition, some RASSF1A polymorphisms lack the tumor suppressor function of RASSF1A and, if present in patients, may be tumorigenic.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697344     DOI: 10.1038/onc.2010.316

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  The RASSF1A tumor suppressor regulates XPA-mediated DNA repair.

Authors:  Howard Donninger; Jennifer Clark; Francesca Rinaldo; Nicholas Nelson; Thibaut Barnoud; M Lee Schmidt; Katharine R Hobbing; Michele D Vos; Brian Sils; Geoffrey J Clark
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

2.  Analysis of Liver Tumor-Prone Mouse Models of the Hippo Kinase Scaffold Proteins RASSF1A and SAV1.

Authors:  Xiaoying Zhang; Cai Guo; Xiwei Wu; Arthur X Li; Limin Liu; Walter Tsark; Reinhard Dammann; Hui Shen; Steven L Vonderfecht; Gerd P Pfeifer
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

3.  RASSF1A: Not a prototypical Ras effector.

Authors:  Marilyn Gordon; Shairaz Baksh
Journal:  Small GTPases       Date:  2011-05

4.  Dual-functionality of RASSF1A overexpression in A375 cells is mediated by activation of IL-6/STAT3 regulatory loop.

Authors:  Mei Yi; Wei Wang; Shengnan Chen; Ya Peng; Junjun Li; Jing Cai; Ying Zhou; Qian Peng; Yuanyuan Ban; Zhaoyang Zeng; Xiaoling Li; Wei Xiong; Guiyuan Li; Bo Xiang
Journal:  Mol Biol Rep       Date:  2018-08-03       Impact factor: 2.316

Review 5.  Ras signaling through RASSF proteins.

Authors:  Howard Donninger; M Lee Schmidt; Jessica Mezzanotte; Thibaut Barnoud; Geoffrey J Clark
Journal:  Semin Cell Dev Biol       Date:  2016-06-08       Impact factor: 7.727

6.  Cell cycle restriction is more important than apoptosis induction for RASSF1A protein tumor suppression.

Authors:  Howard Donninger; Jennifer A Clark; Megan K Monaghan; M Lee Schmidt; Michele Vos; Geoffrey J Clark
Journal:  J Biol Chem       Date:  2014-09-15       Impact factor: 5.157

7.  RASSF1 Polymorphisms in Cancer.

Authors:  Marilyn Gordon; Mohamed El-Kalla; Shairaz Baksh
Journal:  Mol Biol Int       Date:  2012-05-31

8.  The cellular functions of RASSF1A and its inactivation in prostate cancer.

Authors:  Karishma S Amin; Partha P Banerjee
Journal:  J Carcinog       Date:  2012-02-17

9.  RASSF1A and the Taxol Response in Ovarian Cancer.

Authors:  Susannah Kassler; Howard Donninger; Michael J Birrer; Geoffrey J Clark
Journal:  Mol Biol Int       Date:  2012-04-03

10.  Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.

Authors:  Reju Korah; James M Healy; John W Kunstman; Annabelle L Fonseca; Amir H Ameri; Manju L Prasad; Tobias Carling
Journal:  Mol Cancer       Date:  2013-08-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.